Dr. Andre Ghetti is a biotech innovator and translational research leader with deep expertise in molecular biology, neuroscience, and drug discovery. As CEO of AnaBios Corporation and former President of Aviva Biosciences, he has built and commercialized cutting-edge human cell-based platforms for pharmaceutical R&D. Andre’s scientific leadership spans senior roles at Vertex Pharmaceuticals and the Salk Institute, with a proven record of advancing gene therapy, pain research, and translational methodologies. He is a recognized principal investigator on multiple NIH grants and a driving force behind Circurna’s technology and operational strategy.